Apricus Biosciences, Inc (APRI)

Home > Quotes > APRI

APRI

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols

Symbol Lookup

Community Home
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Join Today
Already a member?

Save stocks for next time

| Sponsored

New SEC
Filings

News

Price
Charts

Trade
History

Annual
Report

Earnings
Report Date

Dynamic quotes: Off

Best Bid /Ask:	N/A / N/A
1 Year Target:	5.75
Today's High/Low:	$ 2.70 / $ 2.56
Share Volume:	1,551,980
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume.	337,930
Previous Close:	$ 2.65
52 Week High /Low:	$ 3.6299 / $ 1.89
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.	78,799,508
Annualized dividend	N/A
Ex Dividend Date	N/A
Dividend Payment Date	N/A
Current Yield	0 %
Beta	1.66
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues.	$ 2.68
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ.	May 24, 2013
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities.	$ 2.58
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ.	May 24, 2013
Community Sentiment

Intraday Chart

5d | 1m | 6m | 12m | More Charting

Company Description (as filed with the SEC)

Apricus Biosciences, Inc. was incorporated in Nevada in 1987. Apricus Biosciences, Inc. and it subsidiaries (collectively the “Company”) have operated in the pharmaceutical industry since 1995. As a pharmaceutical company, we develop and commercialize pharmaceutical products that treat large patient populations with operations based in the United States (“U.S.”). Our strategy is to focus our efforts on commercializing our main product and product candidates that are primarily within the field of sexual health. Our products have been developed utilizing our NexACT® proprietary permeation enhancement technology. Our initial approved product is Vitaros® approved in Canada for the treatment of erectile dysfunction (“ED”) and our next in-line late stage product candidate is Femprox ®, for the treatment of female sexual arousal disorder (“FSAD”). ... More ...